Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2025-01-08 Regulatory Filings
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
澄清媒體報導
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company clarifying media reports about its revenue projections. It explicitly states that the company has not prepared financial forecasts and that the media report is speculative. The document is brief (706 characters) and serves as a public clarification rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or regulatory certifications. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement clarifying information to the public and investors.
2025-01-08 Chinese
113年12月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (科妍) reporting on the status of fund loans and endorsement guarantees for the current and previous month, including cumulative amounts and limits. It contains no detailed financial statements, no management discussion, no audit information, and no regulatory certifications. The content is a straightforward regulatory disclosure of financial guarantees and loans, typical of a regulatory filing or compliance announcement. The document length is very short (601 characters), and it does not indicate it is an announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2025-01-07 Chinese
113年12月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a revenue summary report from a listed company, showing monthly and cumulative net operating revenue figures with percentage changes compared to the previous year. It includes notes on accounting standards (IFRS) and reporting practices. The document length is short (767 characters) and it primarily provides financial summary data without detailed financial statements or management discussion. It is not an announcement of a report publication but a brief financial data summary. This fits best with the category of Fund Information / Factsheet (FS), which is a brief summary of key company financials and market info.
2025-01-07 Chinese
公告本公司一針劑型透明質酸”HYAJOINT Plus”關節腔 注射劑產品取得銷售許可證書
Regulatory Filings Classification · 95% confidence The document is a short announcement (802 characters) from a company named 科妍生物科技股份有限公司 about obtaining a sales permit certificate for a medical product (a hyaluronic acid injection). It is a factual announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. There is no indication of financial data, meeting materials, voting results, or legal proceedings. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-01-06 Chinese
113年12月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, managers, and their family members. It shows the number of shares held, changes in holdings, and types of shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a full financial report, earnings release, or meeting materials. The document is a report of personal share transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is sufficient and contains substantive data on insider holdings and changes, confirming it is not a mere announcement or certification.
2025-01-03 Chinese
113年12月董事會成員及持股
Director's Dealing Classification · 100% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors and senior management. It lists individual holdings, pledged shares, and related percentages. The document is short (2484 characters) and focuses on insider shareholdings and pledges. This matches the characteristics of a Director's Dealing report, which reports personal share transactions or holdings by company directors and executives. There is no indication of financial results, meeting materials, or other report types. Therefore, the document is best classified as a Director's Dealing (DIRS) filing.
2025-01-03 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.